ny-eso-1c259-modified t cells
Cell therapyexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2013 (NCT01892293)
Timeline
2010s
- Jan 1, 2013
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Cancer/testis antigen 1Immunity, passive
Cancer/testis antigen 1 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ny-eso-1c259-modified t cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01892293 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2013 | Adaptimmune, University of Pennsylvania |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Adaptimmune | For profit | 1 | 1 | 1 | 2013 |
| University of Pennsylvania | Academic/Hospital | 1 | 0 | 1 | 2013 |
2 organizations
Page 1 / 1